Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naive Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir.

Tytuł:
Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naive Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir.
Autorzy:
Gotti, Daria
Cesana, Bruno Mario
Albini, Laura
Calabresi, Alessandra
Izzo, Liaría
Focà, Emanuele
Motta, Davide
Bellagamba, Rita
Fezza, Rita
Narciso, Pasquale
Sighinolfi, Laura
Maggi, Paolo
Brianese, Nigritella
Quiros-Roldan, Eugenia
Guaraldi, Giovanni
Torti, Carlo
Temat:
CHOLESTEROL
HIGH density lipoproteins
ANTIRETROVIRAL agents
EFAVIRENZ
ATAZANAVIR
RITONAVIR
CARDIOVASCULAR diseases risk factors
HIV-positive persons
COMPARATIVE studies
Źródło:
HIV Clinical Trials; Sep/Oct2012, Vol. 13 Issue 5, p245-255, 11p, 3 Charts, 3 Graphs
Czasopismo naukowe
Background: Cardiovascular risk in HIV-infected patients is related, at least in part, to serum lipid alterations before and after HAART. Lipoprotein-particle subclasses may also have an effect, but comparative data after standard HAART regimens are limited. Methods: This was a substudy of a trial in 91 antiretroviral-naive patients randomized to tenofovir+emtricitabine + atazanavir/ritonavir (ATV/r) or efavirenz (EFV). Over-time trends from baseline to week 48 in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), HDL particles (HDLp), and TC:HDL-C and TG:HDL-C ratios were analyzed by analysis of covariance (ANCOVA). Furthermore, confidence intervals for differences between the 2 groups at week 48 were calculated. Indications for lipid-lowering interventions and low HDL-C were also studied. Results: ANCOVA showed that, with respect to patients receiving ATV/r, those prescribed efavirenz (EFV) had greater increases reported as mean differences in lipid values at week 48:14 mg/dL (95% CI, 0.2 to 27) for TC, 14 mg/dL (95% CI, 4 to 25) for LDL-C, 5 mg/dL (95% CI, 2 to 9) for HDL-C, and 2.2 mg/dL (95% CI, 0.4 to 4) for large HDLp. Proportions of subjects with indications for lipid-lowering interventions and with HDL-C <40 mg/dL did not differ significantly. Conclusions: Patients prescribed EFV had greater increases in TC, LDL-C, and HDL-C. Although no significant differences were detected between the 2 groups for the TC:HDL ratio and for indications to start lipid-lowering interventions, large HDLp increased more in the EFV group compared to the ATV/r group, suggesting a protective effect associated with EFV use. [ABSTRACT FROM AUTHOR]
Copyright of HIV Clinical Trials is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies